Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Value of Considering Cost, and the Cost of Not Considering Value.

Literature DB >> 26668345

The Value of Considering Cost, and the Cost of Not Considering Value.

Leonard B Saltz¹.

Abstract

Mesh：

Substances：
Antineoplastic Agents

Year: 2015 PMID： 26668345 PMCID： PMC5569684 DOI： 10.1200/JCO.2015.64.7867

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

× No keyword cloud information.

2 in total

1. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

Authors: Sham Mailankody; Vinay Prasad
Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777

2. Pricing in the Market for Anticancer Drugs.

Authors: David H Howard; Peter B Bach; Ernst R Berndt; Rena M Conti
Journal: J Econ Perspect Date: 2015

2 in total

11 in total

1. Reply to A. Wong et al.

Authors: Victoria L Chiou; Mauricio Burotto
Journal: J Clin Oncol Date: 2016-02-29 Impact factor: 44.544

2. Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.

Authors: Caitlin R Meeker; Daniel M Geynisman; Brian L Egleston; Michael J Hall; Karen Y Mechanic; Marijo Bilusic; Elizabeth R Plimack; Lainie P Martin; Margaret von Mehren; Bianca Lewis; Yu-Ning Wong
Journal: J Oncol Pract Date: 2016-06-21 Impact factor: 3.840

Review 3. Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

Authors: Leonard B Saltz
Journal: Cancer J Date: 2016 May-Jun Impact factor: 3.360

4. The cost of cancer care is not related to its outcomes.

Authors: Guy Storme; S Dhaese; D Corens; Mark De Ridder
Journal: Ecancermedicalscience Date: 2016-10-28

5. Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan.

Authors: Kosuke Takata; Ken-Ichi Fujita; Yutaro Kubota; Hiroo Ishida; Wataru Ichikawa; Ken Shimada; Takashi Sekikawa; Iori Taki-Takemoto; Daisuke Kamei; Shinichi Iwai; Yasutsuna Sasaki
Journal: J Pharm Health Care Sci Date: 2016-11-09

6. The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.

Authors: Helmy M Guirgis
Journal: J Immunother Cancer Date: 2018-02-20 Impact factor: 13.751

The Value of Considering Cost, and the Cost of Not Considering Value.

1. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

2. Pricing in the Market for Anticancer Drugs.

1. Reply to A. Wong et al.

2. Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.

Review 3. Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

4. The cost of cancer care is not related to its outcomes.

5. Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan.

6. The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.

7. A Patient-Centered Utility Index for Non-Small Cell Lung Cancer in the United States.

8. Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World.

9. Value: The Next Frontier in Cancer Care.

10. Public Health Care Financing and the Costs of Cancer Care: A Cross-National Analysis.